Days 1 and 8 of each 21-day cycle
Recommended dose until disease progression or unacceptable toxicity
Reduce the dosage of FYARRO to 56 mg/m2 when used concomitantly with a moderate or weak cytochrome P-450 3A4 (CYP3A4) inhibitor. Avoid concomitant use with drugs that are strong CYP3A4 and/or P-glycoprotein (P-gp) inhibitors and inducers and with grapefruit and grapefruit juice.
Use in patients with severe hepatic impairment is not recommended. Dose reductions to 75 mg/m2 and 56 mg/m2 are recommended in patients with mild and moderate hepatic impairment, respectively.
See details on clinical trial data along with preparation, dosing, administration, adverse reaction management, and storage and handling.